Sponsored by the Academy for Continued Healthcare Learning
This activity is supported by an educational grant from Amgen, Inc.
Treatment decisions for hyperlipidemia are increasingly challenging due to changing guidelines and a new class of therapies, the PCSK9 inhibitors. Further, clinicians must have competence in identifying high-risk patients who may require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of eligible at-risk patients. Interventional cardiologists require up-to-date knowledge of these new therapies and data since they are likely to encounter high-risk patients with hyperlipidemia.
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, and nurses involved in the management and treatment of patients with hyperlipidemia.
Upon completion of this activity, participants will be able to:
Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
Identify high-risk patients who may be candidates for a PCSK9 inhibitor
Formulate individualized treatment strategies for complex patients based on available evidence
Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Rajesh Dave, MD, FACC, FSCAI (Moderator) Chief Medical Executive Holy Spirit Cardiovascular Institute Chairman, Department of Cardiology Director, Cardiac Catheterization Laboratories The Ortenzio Heart Center at Holy Spirit Hospital Camp Hill, PA
Dr. Dave discloses the following: Board Member/Advisory Panel/Speakers Bureau: Abbott Vascular, Amgen, Aralez, Astellas, Boston Scientific Corporation, Bristol-Myers Squibb, Chiesi USA Inc, Pfizer, QT Vascular, Regeneron, and Sanofi-Aventis Sources of Funding for Research: Abbott Vascular
Nihar Desai, MD, MPH Assistant Professor of Medicine Yale School of Medicine New Haven, CT
Dr. Desai discloses the following: Honoraria: Amgen, Boehringer Ingelheim, Cytokinetics, and Relypsa Research Support: Amgen, Boehringer Ingelheim, and Relypsa
Robert Giugliano, MD, SM Associate Professor of Medicine Brigham and Women’s Hospital Harvard Medical School Boston, MA
Dr. Giugliano discloses the following: Consultant: Amarin, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, CVS Caremark, Daiichi Sankyo, GlaxoSmithKline, Lexicon, Merck, Portola, and Pfizer Honoraria: Amgen, Daiichi Sankyo, and Merck Research Support: Amgen
Accredited Provider Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and the Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Inclisiran
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 60% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Katlyn Cooper email@example.com